2 inhibitors to patients with heart disease. The European Medicines Agency said earlier on Wednesday it would review the cardiovascular safety of COX-2 inhibitors and would strengthen existing warnings about them. Pfizer said on Oct. 1 that three long-term studies seeking additional uses for Celebrex have turned up no cardiovascular safety concerns. --SP 2339 Local Time 2039 GMT